Tag: healthcare
-
Sanofi’s Pipeline Reset Signals a New Era of R&D Discipline
Sanofi’s latest pipeline review highlights a shift from expanding R&D portfolios to making more disciplined investment decisions. Here’s why that matters for the future of big pharma.
-
Why Big Pharma Is Buying Biotech Again: The Patent Cliff Explained
Patent expirations are reshaping the pharmaceutical industry. Here’s why Big Pharma is buying biotech companies again—and what investors should watch next.
-
Lilly & Novo Nordisk Reach Landmark Pricing Agreement with U.S. Government on Obesity Drugs
As the battle for dominance in obesity treatment intensifies, Eli Lilly and Novo Nordisk are racing ahead with groundbreaking drugs. But with politics and market power in play, the story goes far beyond science — it’s shaping the future of healthcare itself.
-
The Battle for Metsera: Pfizer and Novo Nordisk in a Fierce Takeover War
As the race for next-generation obesity treatments intensifies, two global pharma giants — Pfizer and Novo Nordisk — are locked in a fierce takeover battle over Metsera, a promising biotech with breakthrough GLP-1 assets. What began as a merger deal has escalated into a high-stakes legal and strategic war.